Disparities in the presence of driver mutations and response to tyrosine kinase inhibitors in young patients with lung cancer

被引：0
|
作者：
Edwards, Kyle
Rose, Brandon
Lopes, Gilberto
Rodriguez, Estelamari
Olazagasti, Coral
机构：
来源：
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | 2024年 / 33卷 / 09期
关键词：
D O I：
10.1158/1538-7755.DISP24-A106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A106
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
    Brindel, Aurelien
    Althakfi, Wajd
    Barritault, Marc
    Watkin, Emmanuel
    Maury, Jean-Michel
    Bringuier, Pierre-Paul
    Girard, Nicolas
    Brevet, Marie
    JOURNAL OF THORACIC DISEASE, 2020, 12 (09) : 4643 - +
  • [2] Tyrosine Kinase Inhibitors in Lung Cancer
    Thomas, Anish
    Rajan, Arun
    Giaccone, Giuseppe
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2012, 26 (03) : 589 - +
  • [3] Understanding biological driver mutations and mechanism of resistance to EGFR-tyrosine kinase inhibitors in lung cancer patients using a novel translational platform.
    Babu, Govind K.
    Chaudhuri, Padmaparna
    Koppak, Deepak
    Biswas, Manjusha
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] The role of autophagy in tyrosine kinase inhibitors treatment of lung cancer depending on the presence of different EGFR gene mutations.
    Baidyuk, E.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2020, 50 : 73 - 73
  • [5] Uncommon EGFR mutations in lung adenocarcinomas: Clinical features and response to tyrosine kinase inhibitors
    Brindel, A.
    Althakfi, W.
    Barritault, M.
    Bringuier, P-P.
    Watkin, E.
    Maury, J-M.
    Girard, N.
    Brevet, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
    Yao, Yu
    Yang, Huaping
    Zhu, Bo
    Wang, Song
    Pang, Jiaohui
    Wu, Xiaoying
    Xu, Yang
    Zhang, Junli
    Zhang, Jinfeng
    Ou, Qiuxiang
    Tian, Hui
    Zhao, Zheng
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [7] Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
    Yu Yao
    Huaping Yang
    Bo Zhu
    Song Wang
    Jiaohui Pang
    Xiaoying Wu
    Yang Xu
    Junli Zhang
    Jinfeng Zhang
    Qiuxiang Ou
    Hui Tian
    Zheng Zhao
    Respiratory Research, 24
  • [8] Role of Tyrosine Kinase Inhibitors in Lung Cancer
    Ansari, J.
    Palmer, D. H.
    Rea, D. W.
    Hussain, S. A.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (05) : 569 - 575
  • [9] Novel Tyrosine Kinase Inhibitors in Lung Cancer
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S86 - S87
  • [10] Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones
    Marchetti, Antonio
    Milella, Michele
    Felicioni, Lara
    Cappuzzo, Federico
    Irtelli, Luciana
    Del Grammastro, Maela
    Sciarrotta, Mariagrazia
    Malatesta, Sara
    Nuzzo, Carmen
    Finocchiaro, Giovanna
    Perrucci, Bruno Bp
    Carlone, Donatella
    Gelibter, Alain J.
    Ceribelli, Anna
    Mezzetti, Andrea
    Iacobelli, Stefano
    Cognetti, Francesco
    Buttitta, Fiamma
    NEOPLASIA, 2009, 11 (10): : 1084 - 1092
12345